Skip to Main Content

The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use of a patent to block competitors for some of its medicines, the latest instance in which European authorities have probed drug companies for antitrust infractions.

Earlier this week, the Swiss agency conducted a dawn raid on Novartis headquarters in Basel, Switzerland, seeking information about efforts the company allegedly made to protect a drug for an unspecified skin treatment. Novartis sells a psoriasis medication called Cosentyx, which is its biggest seller and generated more than $2.4 billion in sales in the first half of 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment